|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.845 CAD | -0.18% |
|
-0.52% | +2.71% |
| Nov. 12 | Cronos Group Inc. Reports Impairment Charges for the Third Quarter Ended September 30, 2024 | CI |
| Nov. 12 | Cronos Group Inc., Q3 2024 Earnings Call, Nov 12, 2024 |
| Capitalization | 1.09B 771M 729M 676M 603M 65.47B 1.19B 8.41B 3.1B 26.86B 2.9B 2.83B 117B | P/E ratio 2024 * |
-67.9x | P/E ratio 2025 * | 103x |
|---|---|---|---|---|---|
| Enterprise value | 1.09B 771M 729M 676M 603M 65.47B 1.19B 8.41B 3.1B 26.86B 2.9B 2.83B 117B | EV / Sales 2024 * |
6.29x | EV / Sales 2025 * | 5.51x |
| Free-Float |
52.41% | Yield 2024 * |
-
| Yield 2025 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Cronos Group Inc.
More recommendations
More press releases
| 1 day | -2.06% | ||
| 1 week | -2.40% | ||
| Current month | -2.73% | ||
| 1 month | +1.79% | ||
| 3 months | -4.04% | ||
| 6 months | -15.68% | ||
| Current year | +2.89% |
1 week
2.79
3.00
1 month
2.663.26
Current year
2.564.28
1 year
2.484.28
3 years
2.155.85
5 years
2.1520.08
10 years
0.1432.95
| Director | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 37 | 2022-03-20 | |
James Holm
DFI | Director of Finance/CFO | 41 | 2022-11-13 |
Arye Weigensberg
CTO | Chief Tech/Sci/R&D Officer | 41 | - |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chairman | 37 | 2017-03-01 | |
Jason Adler
BRD | Director/Board Member | 52 | 2016-07-11 |
James Rudyk
BRD | Director/Board Member | 57 | 2018-01-31 |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -2.06% | -2.40% | -0.35% | -49.82% | 771M | ||
| -0.14% | -1.37% | +14.45% | +29.00% | 5.08B | ||
| -0.47% | -2.59% | -32.00% | +1.62% | 3.9B | ||
| -0.82% | -1.97% | -8.32% | +3.59% | 2.97B | ||
| -1.25% | -2.68% | -8.64% | +19.99% | 2.91B | ||
| -0.70% | -0.12% | -3.41% | -9.44% | 2.49B | ||
| -0.71% | +0.24% | -3.89% | -3.00% | 1.74B | ||
| -2.79% | -2.39% | +29.91% | +60.82% | 1.68B | ||
| -0.71% | -2.65% | -4.24% | -17.51% | 1.63B | ||
| -2.14% | -3.96% | +67.51% | +103.20% | 1.56B | ||
| Average | -1.18% | -1.76% | +5.10% | +13.84% | 2.47B | |
| Weighted average by Cap. | -0.90% | -1.61% | +1.29% | +15.76% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 173M 123M 116M 108M 95.88M 10.4B 190M 1.34B 493M 4.27B 460M 450M 18.52B | 198M 140M 132M 123M 109M 11.88B 217M 1.53B 563M 4.87B 526M 514M 21.14B |
| Net income | -17.88M -12.66M -11.97M -11.1M -9.9M -1.07B -19.59M -138M -50.96M -441M -47.56M -46.52M -1.91B | 14.35M 10.16M 9.6M 8.91M 7.95M 862M 15.72M 111M 40.89M 354M 38.16M 37.33M 1.53B |
| Net Debt | - | - |
More financial data
* Estimated data
Employees
356
Sector
Pharmaceuticals
Calendar
2025-03-03
- Q4 2024 Earnings Release (Projected)
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-12-10 | 2.845 $ | -0.18% | 70,010 |
| 24-12-09 | 2.850 $ | -2.06% | 159,464 |
| 24-12-06 | 2.910 $ | +2.83% | 71,511 |
| 24-12-05 | 2.830 $ | -1.05% | 107,135 |
| 24-12-04 | 2.860 $ | 0.00% | 228,269 |
Delayed Quote Toronto S.E., December 09, 2024 at 04:00 pm EST
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
2.850CAD
Average target price
3.566CAD
Spread / Average Target
+25.12%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- CRON Stock